Adalat CC Articles
OPPORTUNITIES FROM DRUG DELIVERY SYSTEMS
21 February 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
NIFEDIPINE TRIAL ENROLLMENT IN JAPAN
11 October 1993
NEW TRIAL RESULTS REPORTED AT ECCO
20 September 1993
CIRCA'S 1ST PRODUCT APPROVED BY FDA
16 August 1993
SUSTAINABLE EARNINGS GROWTH FOR SANDOZ
16 August 1993
NICOTINE PATCH COs SUFFER DECLINE IN US SALES
2 August 1993
BAYER FILES LAWSUIT
26 July 1993
ADVANCES BY US DRUG COMPANIES IN 2nd QTR
26 July 1993
CELLTECH'S CGRP IN RAYNAUD'S DISEASE
19 July 1993
NEW YORK STOCK COMMENT
12 July 1993
IMPORTS OF AUSTRIAN DRUGS EASIER
12 July 1993
US PRESCRIBING TRENDS IN MARCH
28 June 1993
ALZA FORECAST
28 June 1993
US DRUGMAKERS AND "THE BLACK HOLE"
21 June 1993
LISINOPRIL META-ANALYSIS
14 June 1993
BAYER'S GLUCOBAY LAUNCHED IN UK
14 June 1993
THREE-WAY GENERIC AGREEMENT
31 May 1993
PFIZER "CONFIDENT" IN CHANGING ENVIRONMENT
3 May 1993
PFIZER CONSIDERS PRICE CUTS
29 March 1993
YAMANOUCHI'S YM-430 IN PHASE I TRIALS
8 March 1993
GENTA'S JAGOTEC IN JV WITH GENSIA
22 February 1993
PFIZER DISREGARDS WSJ "SCARE STORY"
15 February 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
ALZA is STILL A STRONG BUY
14 December 1992
US RESULTS 3RD QTR
2 November 1992
ANTIHYPERTENSIVES IN DIABETICS
2 November 1992
FOCUS ON IVAX PRODUCT PIPELINE
12 October 1992
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
PLENDIL LAUNCHED IN GERMANY
7 September 1992
ELAN CORP FUTURE LOOKS BETTER THAN EXPECTED
3 August 1992
JAPAN'S NEW PHARMA TARIFF
3 August 1992
GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs
3 August 1992
HYPERTENSION OPTIMAL TREATMENT STUDY
22 June 1992
ZANTAC TOPS MAIL ORDER SALES IN USA
8 June 1992
ASTRA'S PLENDIL HEADING FOR CHF INDICATION
25 May 1992
JAPAN SUBSIDS DO WELL FOR MNCs
18 May 1992
GOOD 1st QTRs for ALZA, IMMUNEX AND MYLAN
4 May 1992
US NEW PRESCRIPTI0N DRUG SALES IN 1991
13 April 1992
US PRESCRIPTION PRICES UP 8.1%IN 1991
23 March 1992
VOLUME GROWTH FOR US DRUGMAKERS
9 March 1992
MEDEVA'S NEW CORACTEN FORM
9 March 1992
US GENERIC DRUG MARKET TO 1995
17 February 1992
ALZA PRODUCT PROMOTIONS
20 January 1992
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
